Skip to main content
. 2022 Sep 22;108(2):555–567. doi: 10.3324/haematol.2022.280995

Figure 2.

Figure 2.

SUMO inhibition is an effective therapy for Myc-driven B-cell lymphoma in vivo. (A) Schematic illustration showing transplantation of Em-myc lymphoma cells (CD45.2) into wild-type (wt) (CD45.1) recipient mice. Mice were treated with carrier or SUMO inhibitor (SUMOi) (ML-093, 50 mg/kg) at day 7 post transplantation. Analysis of bone marrow, spleen and blood was performed at day 9, n=6 per condition. (B) Pie charts representing the frequencies of wt and Em-myc lymphoma cells in the bone marrow (BM) and spleen after carrier vs. SUMOi treatment. (C) Total number of Em-myc lymphoma cells in the BM and spleen following SUMOi treatment compared to carrier. N=6, P values were determined by unpaired t-test. (D) Pie charts representing the frequencies of B cells (B220+), T cells (CD3+), granulocytes (Gr.1+CD11b+) and monocytes (Gr.1- CD11b+) in the BM and spleen after carrier vs. SUMOi treatment. i.v.: intravenously.